Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
Journal
European journal of cancer (Oxford, England : 1990)
Journal Volume
152
Pages
68
Date Issued
2021
Author(s)
Gelmon, Karen A
Fasching, Peter A
Couch, Fergus J
Balmaña, Judith
Delaloge, Suzette
Labidi-Galy, Intidhar
Bennett, James
et al.
Abstract
In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a setting reflecting clinical practice.
Subjects
BRCA1 gene; BRCA2 gene; Breast cancer; Effectiveness; Germline mutation; Metastatic; Olaparib; Progression-free survival; Treatment outcome
SDGs
Publisher
ELSEVIER SCI LTD
Type
journal article